New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 14, 2013
07:41 EDTSNYSanofi R&D focused on biology of disease, WSJ reports
Dr. Elias Zerhouni, a former director of the U.S. National Institutes of Health, and now head of R&D at Sanofi (SNY) is attempting to shift to an earlier stage of research and development, and boost the number and quality of the company's drug discoveries. He has recruited about 20 new R&D leaders to help Sanofi become better at understanding how diseases work and how to target them. "We're investing a lot more upstream in understanding human-disease biology," he says. "We're extremely good at toolmaking," he added, referring to the formulation of new pills and shots, "but not very good at understanding the biology" of disease.Reference Link
News For SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 12, 2016
13:55 EDTSNYRBC thinks Intercept values itself more than any bidder can pay
RBC Capital analyst Michael Yee believes Intercept Pharmaceuticals (ICPT) thinks it is worth more than a bidder would be willing to pay at this time. Suitor interest is not surprising given Intercept's pending approval in the summer, but a near-term takeover is unlikely since the FDA hasn't even held a panel meeting for the company's lead drug OCA, Yee tell investors in a research note after Reuters reported that the company received interest and is exploring a possible sale. The analyst thinks Intercept could be synergistic for companies like Gilead (GILD), Merck (MRK), Bristol-Myers (BMY), Sanofi (SNY) and AstraZeneca (AZN). Yee has an Outperform rating on stock with a $300 price target. Intercept is rallying 25%, or $24.07, to $118.36 in afternoon trading.
February 11, 2016
07:17 EDTSNYLeerink to hold a conference
Subscribe for More Information
February 9, 2016
12:25 EDTSNYRegeneron price target lowered to $443 from $607 at Piper Jaffray
Subscribe for More Information
08:08 EDTSNYSanofi sees FY16 business EPS to be broadly stable at CER
Subscribe for More Information
05:28 EDTSNYSanofi reports Q4 business EPS down 5.8% to EUR 1.31
Subscribe for More Information
February 8, 2016
06:28 EDTSNYPharma trade group rolls out ad campaign aimed at lawmakers, WSJ says
The pharmaceutical industry is launching a new ad campaign with the intention of improving its reputation with lawmakers in an effort to lobby against drug price restrictions, the Wall Street Journal reports. The industry's biggest trade group the Pharmaceutical Research and Manufacturers of America, or PhRMA, says it plans to spend several million dollars this year, and 10% more than it spent last year, on digital, radio, and print advertisements that highlight the sector's role in developing new drugs and advancing medical science, the report says. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Reference Link
February 2, 2016
11:09 EDTSNYSanofi plans to cut 600 jobs in France over three years, Bloomberg reports
Subscribe for More Information
07:24 EDTSNYSanofi, Merck mulling exiting vaccine JV, Bloomberg reports
Subscribe for More Information
05:19 EDTSNYSanofi Pasteur launches R&D project targeting prevention of Zika virus infection
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use